Innovative Health Initiative (IHI)’s Post

🌟CALLING ALL PHARMACEUTICAL PROFESSIONALS! Join us at the WOCIP Cluster Meetings, where collaboration sparks innovation! See the exciting topics covered in all four targeted business meetings below! Stay tuned as we unveil the unique topics for each day! Join forces with peers in your role across the industry to tackle barriers to health equity together! 🌎 REGISTER BY APRIL 12th AND GET 50% OFF. Use the link and code in the comments. #WOCIP #HealthEquity #PharmaIndustry

𝐀𝐥𝐦𝐚𝐜 𝐀𝐧𝐧𝐨𝐮𝐧𝐜𝐞𝐬 𝐈𝐧𝐯𝐞𝐬𝐭𝐦𝐞𝐧𝐭 𝐢𝐧 𝐒𝐢𝐧𝐠𝐚𝐩𝐨𝐫𝐞 𝐭𝐨 𝐄𝐧𝐡𝐚𝐧𝐜𝐞 𝐂𝐨𝐥𝐝 𝐂𝐡𝐚𝐢𝐧 𝐅𝐚𝐜𝐢𝐥𝐢𝐭𝐲 𝐟𝐨𝐫 𝐆𝐥𝐨𝐛𝐚𝐥 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥 𝐒𝐩𝐨𝐧𝐬𝐨𝐫𝐬 𝐚𝐧𝐝 𝐏𝐚𝐭𝐢𝐞𝐧𝐭𝐬 Almac Clinical Services is proud to announce a significant investment to enhance our frozen facility in Singapore! This expansion will quadruple the current floorspace and add 480 storage locations, boosting our capabilities to support global pharmaceutical sponsors. Our advanced facility, operating between -25°C to -15°C, includes a secondary production room, perfect for managing temperature-sensitive clinical supplies. This strategic move aligns with industry trends and the increasing demand for sophisticated cold chain solutions. Kevin Cheong Yan Foong, Director of Clinical Operations, states: "Our continuous improvements in biologics support ensure patients worldwide receive the highest quality care. This investment reflects our commitment to excellence and innovation." 𝐋𝐞𝐚𝐫𝐧 𝐦𝐨𝐫𝐞: https://lnkd.in/g6kE9NQu 𝐒𝐭𝐚𝐲 𝐮𝐩𝐝𝐚𝐭𝐞𝐝 𝐨𝐧 𝐨𝐮𝐫 𝐥𝐚𝐭𝐞𝐬𝐭 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭𝐬:  https://lnkd.in/gkDAjWnN #AlmacClinicalServices #ColdChain #Pharmaceuticals #SingaporeExpansion #ClinicalSupplyChain #GlobalHealth #TemperatureControl #Biopharma #HealthcareInnovation #PatientCare #ClinicalResearch #SupplyChainManagement #Biotech #LifeSciences #SupplyWithCare

Colonis Commercial Director Michael Dobson and Product Manager Fiona Wiles are attending 30th Medicines for Europe conference later this week in Dublin, where they will be exploring further opportunities for innovation in value-added medicines (VAMs).   Medicines for Europe have a mission to establish, in collaboration with patients, healthcare professionals and payers, a sustainable market model that incentivises R&D and access to VAMs. Here at Colonis Pharma we understand the importance of VAMs which contribute to addressing unmet patient needs, moving from a one-size-fits-all to a more patient specific approach. This is why we are continually investing in the repurposing and reformulation of existing drugs.     Find out more about VAMs at: https://lnkd.in/ef2Mhdch   #Pharmaceuticals #ValueAddedMedicines #MedicinesForEurope

Germany's Pioneering DIGA Act Spurs Digital Health Innovation, With Limits While the RCTs required to meet DiGA’s standards are not as onerous as traditional pharmaceutical pivotal trials, they are still time-consuming, and the statue allows manufacturers to get an extendable one-year listing based on preliminary evidence, which enables them to generate revenue while they complete the more rigorous studies required for a permanent listing (see Figure 1 below). Germany’s high-profile DiGA legislation has successfully encouraged digital therapeutics innovation, according to two new studies, although critics say it still leaves room for improvement. The US company Enovis, which embraces digital therapeutics as a promising business, and its German start-up partner Orthopy Health GmbH are testing the DiGA waters in what Enovis considers to be an important ex-US market opportunity: https://bit.ly/4eWlwj6 #digitaltherapeutics #digitalhealth #medtechinnovation #digitalhealthinnovation #Germany #medtech

Looking forward to the discussion on further innovation in value added medicines including repurposing, reformulations and device innovation

Zentiva is at the forefront of ensuring sustainable healthcare in Europe and our CEO Steffen Saltofte reinforced that commitment at the inaugural launch of the EU's Critical Medicines Alliance.    Industry leaders and policymakers met in Brussels to advance the stability and accessibility of medicine supplies throughout Europe.     With robust manufacturing sites in the Czech Republic and Romania, and a team of more than 5,000 people, Zentiva is a cornerstone in Europe’s pharmaceutical industry. We are devoted to supporting the EU's vision of building a robust healthcare system that ensures high-quality, accessible pharmaceutical solutions are available to all.     Our participation in the Alliance underscores our commitment. We will continue to advocate for policies that enhance the growth of a resilient European healthcare systems. We focus on the continuity and security of medicine supplies, crucial for patient care across the continent.     #Zentiva #CriticalMedicinesAlliance #MedicineAccessibility #Accesstohealthcare

🗨 🚀 Listen to the interesting conversation with our CEO Richard Francis. He talks about the transformation Teva is going through and the huge steps we are making. Encouraging to hear. #weareallinforbetterhealth #tevapharm #pharmastrategy #innovativemedicines #futuregrowth

Our CEO, Steffen Saltofte, participated as a panelist at the 65th GIRP - European Healthcare Distribution Association Annual Meeting & Conference in #Prague, the home of Zentiva's global headquarters, R&D, manufacturing site, and commercial operations. 🇨🇿 During the session titled "Rethinking Value in Healthcare: Transforming the Consumer Experience," Steffen shared his insights on the evolving pharmaceutical landscape, the impact of recent global events, and Zentiva's innovative strategies aimed at extending healthcare access to millions of people. Steffen emphasized the importance of European medicines production, stating, "Ensuring local pharmaceutical production is vital for safeguarding Europe's healthcare resilience. At #Zentiva, we are committed to delivering high-quality, affordable medicines that meet the needs of patients across Europe and beyond." This session explored how medicines are set to transform patient journeys, and reaffirmed our commitment to providing health and wellbeing for all generations. #HealthcareInnovation #GIRP2024 #Pharmaceuticals

#UpcomingAssignmentAtBHFConference I can't wait to professionally facilitate this very important conversation regarding new or innovative ways of contracting in the pharmaceutical space. Value based contracting or outcomes based contracting or performance based contracting...which properly implemented can be a win-win for all stakeholders, patients from an access point of view, funders from a lower cost point of view, and pharma companies from a bigger and more satisfied client base. There isn't a one size fits all approach to value based contracting, and there are pros and cons to be carefully considered just like any other new way of doing things (change introduction), therefore listening to experts on this very important approach to pharma contracting will be very crucial especially for funders and patients, and there is no better place to have this crucial discussion than at the BHF Conference, a gathering of most medical schemes in Southern Africa. Ruth Field 🇿🇦 Asa Skiti Deepak Arora

It is my best opportunity to share my acquaintance with everyone here that I was delighted to attend the FIP digital event by the International pharmaceutical Federation. The theme was "The patient Voice in Generic Medicine Development" which was conducted on 15th November 2022. The objective of the event was: 1. The FDA's perspective on a patient's role in Drug Development. 2. How the Office of Generic (OGD) Drug is working on Patients engagement. # FDA has a wise perspective on a patient's role in drug development. They have organized : * FDA patient representative program * FDA patient listening session * CDER patient focused drug development * Patient Engagement Collaborative OGD patient focused initiatives: 1. OGD focuses on patient accessibility and affordability of medication. 2. Prioritizing beyond the first generic helps drive down the cost of treatment. 3. Prioritizing the assessment of other key drug products such as those in shortage or supporting a public health emergency.